Caris Life Sciences, Inc. Common Stock - Asset Resilience Ratio

Latest as of June 2026: 8.31%

Caris Life Sciences, Inc. Common Stock (CAI) has an Asset Resilience Ratio of 8.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Caris Life Sciences, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$102.20 Million

Cash + Short-term Investments

Total Assets

$1.23 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2025)

This chart shows how Caris Life Sciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CAI total assets.

Liquid Assets Composition Over Time

This chart breaks down Caris Life Sciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Caris Life Sciences, Inc. Common Stock for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$102.20 Million	8.31%
Total Liquid Assets	$102.20 Million	8.31%

Asset Resilience Insights

Limited Liquidity: Caris Life Sciences, Inc. Common Stock maintains only 8.31% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Caris Life Sciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio

Compare Caris Life Sciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Caris Life Sciences, Inc. Common Stock (2009–2025)

The table below shows the annual Asset Resilience Ratio data for Caris Life Sciences, Inc. Common Stock.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.20%	$2.29 Million	$1.13 Billion	-0.44pp
2024-12-31	0.64%	$2.20 Million	$343.73 Million	-15.15pp
2023-12-31	15.79%	$65.18 Million	$412.90 Million	-26.37pp
2022-12-31	42.16%	$302.43 Million	$717.42 Million	+39.13pp
2020-12-31	3.02%	$78.99 Million	$2.61 Billion	+0.50pp
2018-12-31	2.52%	$75.97 Million	$3.01 Billion	+1.28pp
2017-12-31	1.24%	$30.06 Million	$2.43 Billion	+0.27pp
2016-12-31	0.97%	$19.96 Million	$2.06 Billion	-0.09pp
2015-12-31	1.07%	$21.16 Million	$1.99 Billion	+0.05pp
2014-12-31	1.01%	$18.15 Million	$1.80 Billion	+0.23pp
2013-12-31	0.78%	$13.00 Million	$1.68 Billion	+0.01pp
2012-12-31	0.77%	$10.62 Million	$1.39 Billion	+0.12pp
2011-12-31	0.65%	$6.16 Million	$953.37 Million	+0.00pp
2010-12-31	0.64%	$3.95 Million	$613.45 Million	-1.17pp
2009-12-31	1.81%	$6.78 Million	$374.08 Million	--

pp = percentage points

About Caris Life Sciences, Inc. Common Stock

NASDAQ:CAI USA Biotechnology

Market Cap

$8.06 Billion

Market Cap Rank

#2923 Global

#1042 in USA

Share Price

$28.50

Change (1 day)

+9.40%

52-Week Range

$14.55 - $33.53

All Time High

$39.30